Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib

Clinical Cancer Research

Volumn 19, Issue 16, 2013, Pages 4359-4370

  Furmanski, Brian D ^a,b   Hu, Shuiying ^a   Fujita, Ken Ichi ^a,c   Li, Lie ^a   Gibson, Alice A ^a   Janke, Laura J ^a   Williams, Richard T ^a,d   Schuetz, John D ^a   Sparreboom, Alex ^a   Baker, Sharyn D ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b SIGA Technologies Incorporated   (United States)

^c SHOWA UNIVERSITY   (Japan)

^d Puma Biotechnology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; MULTIDRUG RESISTANCE PROTEIN 4;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG TRANSPORT; EX VIVO STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH; STOMACH PH; TIME TO MAXIMUM PLASMA CONCENTRATION; WILD TYPE;

ABSORPTION; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; GASTRIC MUCOSA; HUMANS; MALE; MICE; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STOMACH; THIAZOLES;

EID: 84882950621     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0980     Document Type: Article

References (53)

1. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leu-kemias. N Engl J Med 2006;354:2531-41.
2. Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 2008;36:1357-64.
3. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, et al. Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos 2008;36: 1828-39.
4. Demetri GD, Lo Russo P, MacPherson IRJ, Wang D, Morgan JA, Brunton VG, et al. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 2009;15:6232-40.
5. Zwaan CM, Rizzari C, Mechinaud F, Lancaster DL, Lehrnbecher T, Van der Velden VH, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative for Children with Cancer Consortium. J Clin Oncol 2013;31:2460-8.
6. Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, Gurney H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol 2012;30:4017-25.
7. Luo FR, Yang Z, Camuso A, Smykla R, McGlinchey K, Fager K, et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 2006;12:7180-6.
8. Dai G, Pfister M, Blackwood-Chirchir A, Roy A. Importance of characterizing determinants of variability in exposure: application to dasa-tinib in subjects with chronic myeloid leukemia. J Clin Pharmacol 2008;48:1254-69.
9. Lagas JS, van Waterschoot RA, van Tilburg VA, Hillebrand MJ, Lan-kheet N, Rosing H, et al. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res 2009; 15:2344-51.
10. Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, Elmquist WF. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther 2009;330:956-63.
11. Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick S, Li L, et al. Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 2013;19:1458-66.
12. van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009;35:692-706.
13. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009;15: 6062-9.
14. de Waart DR, van de Wetering K, Kunne C, Duijst S, Paulusma CC, Oude Elferink RP. Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos 2012;40:515-21.
15. Ming X, Thakker DR. Role of basolateral efflux transporter MRP4 in the intestinal absorption of the antiviral drug adefovir dipivoxil. Biochem Pharmacol 2010;79:455-62.
16. Franke RM, Lancaster CS, Peer CJ, Gibson AA, Kosloske AM, Orwick SJ, et al. Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther 2011;89:693-701.
17. Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, et al. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008;14:3141-8.
18. Kamath AV, Wang J, Lee FY, Marathe PH. Preclinical pharmacokinet-ics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol 2008;61:365-76.
19. Gardner ER, Smith NF, Figg WD, Sparreboom A. Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice. J Exp Clin Cancer Res 2009;28:99.
20. Li J, Brahmer J, Messersmith W, Hidalgo M, Baker SD. Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs 2006;24:291-7.
21. Bijlsma PB, Peeters RA, Groot JA, Dekker PR, Taminiau JA, Van Der Meer R. Differential in vivo and in vitro intestinal permeability to lactulose and mannitol in animals and humans: a hypothesis. Gastro-enterology 1995;108:687-96.
22. Emoto C, Yamazaki H, Yamasaki S, Shimada N, Nakajima M, Yokoi T. Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes. Xenobiotica 2000;30: 943-53.
23. Christopher LJ, Cui D, Li W, Barros A Jr, Arora VK, Zhang H, et al. Biotransformation of [14C]dasatinib: invitro studies in rat, monkey, and human and disposition after administration to rats and monkeys. Drug Metab Dispos 2008;36:1341-56.
24. Kitamura Y, Hirouchi M, Kusuhara H, Schuetz JD, Sugiyama Y. Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3). J Pharmacol Exp Ther 2008;327:465-73.
25. Passamonti S, Vrhovsek U, Vanzo A, Mattivi F. The stomach as a site for anthocyanins absorption from food. FEBS Lett 2003;544: 210-3.
26. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 2004;24:7612-21.
27. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 2002;303:323-32.
28. Boulos N, Mulder HL, Calabrese CR, Morrison JB, Rehg JE, Relling MV, et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011;117:3585-95.
29. Hu S, Niu H, Inaba H, Orwick S, Rose C, Panetta JC, et al. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst 2011;103:893-905.
30. Hu S, Niu H, Minkin P, Orwick S, Shimada A, Inaba H, et al. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Mol Cancer Ther 2008;7:1110-20.
31. Baker SD, Hu S. Pharmacokinetic considerations for new targeted therapies. Clin Pharmacol Ther 2009; 85: 208-11.
32. Cheepala SB, Sukthankar M, Schuetz JD. MRP4 (ABCC4). In:Ishikawa T, Kim RB, Konig J, editors. Pharmacogenomics of human drug transporters: clinical impacts. Hoboken, NJ: John Wiley & Sons, Inc.; 2013. p. 365-85.
33. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 2003;38:374-84.
34. Morgan JA, Cheepala SB, Wang Y, Neale G, Adachi M, Nachagari D, et al. Deregulated hepatic metabolism exacerbates impaired testosterone production in Mrp4-deficient mice. J Biol Chem 2012;287: 14456-66.
35. Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008;14:3881-8.
36. Eley T, Luo FR, Agrawal S, Sanil A, Manning J, Li T, et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol 2009;49:700-9.
37. Nies AT, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 2011:105-67.
38. Takenaka K, Morgan JA, Scheffer GL, Adachi M, Stewart CF, Sun D, et al. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res 2007;67:6965-72.
39. van de Waterbeemd H, Jones BC. Predicting oral absorption and bioavailability. Prog Med Chem 2003;41:1-59.
40. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26.
41. Dobson PD, Kell DB. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 2008;7:205-20.
42. Hollander D, Dadufalza VD, Fairchild PA. Intestinal absorption of aspirin. Influence of pH, taurocholate, ascorbate, and ethanol. J Lab Clin Med 1981;4:591-8.
43. Mattiello T, Guerriero R, Lotti LV, Trifiro E, Felli MP, Barbarulo A, et al. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. J Am Coll Cardiol 2011;58:752-61.
44. Fallingborg J. Intraluminal pH of the human gastrointestinal tract. Dan Med Bull 1999;46:183-96.
45. Matsuoka A, Takahashi N, Miura M, Niioka T, Kawakami K, Matsunaga T, et al. H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2012;70:351-2.
46. Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinet-ics in Japanese leukemia patients. Cancer Chemother Pharmacol 2012;69:999-1004.
47. Pavlovsky C, Egorin MJ, Shah DD, Beumer JH, Rogel S, Pavlovsky S. Imatinib mesylate pharmacokinetics before and after sleeve gastrec-tomy in a morbidly obese patient with chronic myeloid leukemia. Pharmacotherapy 2009;29:1152-6.
48. Yoo C, Ryu MH, Kang BW, Yoon SK, Ryoo BY, Chang HM, et al. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 2010;28: 1554-9.
49. Kim KP, Ryu MH, Yoo C, Ryoo BY, Choi DR, Chang HM, et al. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. Cancer Chemother Pharmacol 2011;68:285-91.
50. Egorin MJ, Shah DD, Christner SM, Yerk MA, Komazec KA, Appleman LR, et al. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br J Clin Pharmacol 2009;68:370-4.
51. Yin OQ, Gallagher N, Fischer D, Demirhan E, Zhou W, Golor G, et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol 2010;50:960-7.
52. Tougas G, Earnest DL, Chen Y, Vanderkoy C, Rojavin M. Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by tegaserod. Aliment Pharmacol Ther 2005;22:59-65.
53. Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP. Differential effects of dose regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clin Pharmacol 2013;5:85-97.